Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - TTC28 |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - TTC28 | cholangiocarcinoma | sensitive | Infigratinib | Preclinical - Pdx | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of cholangiocarcinoma harboring FGFR2-TTC28 fusion (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). | detail... | |
FGFR2 - TTC28 | intrahepatic cholangiocarcinoma | predicted - sensitive | Futibatinib | Case Reports/Case Series | Actionable | In a Phase I trial, Futibatinib (TAS-120) treatment at a dose of 16mg led to a partial response in 42.1% (8/19) of patients with intrahepatic cholangiocarcinoma harboring FGF or FGFR alterations, including a partial response with a progression-free survival of 24.1 months and a duration of response of 12.7 months in a patient harboring FGFR2-TTC28 (PMID: 34551969; NCT02052778). | 34551969 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|